Best peptides for muscle growth
Peptides that stimulate growth hormone release, enhance recovery, or support lean tissue development for building muscle.
What to know
GH secretagogues (ipamorelin, CJC-1295) promote muscle growth indirectly through elevated growth hormone and IGF-1. They work best combined with proper training, nutrition, and sleep. MK-677 is oral but watch for appetite increase and water retention. BPC-157 and TB-500 support recovery between sessions. None of these are anabolic steroids — expect subtle, gradual improvements over 3-6 months.
Recommended peptides
Ipamorelin
gh-secretagogue
Ipamorelin is a synthetic pentapeptide and growth hormone releasing peptide (GHRP) that stimulates the pituitary gland to secrete growth hormone through selective activation of the ghrelin receptor (GHS-R1a). Developed in the late 1990s by Novo Nordisk, it was characterized in a landmark 1999 study as the first GHRP to release GH with absolute selectivity, meaning it does not significantly elevate cortisol, prolactin, ACTH, FSH, or LH at pharmacological doses (PMID: 10580762). This hormonal selectivity distinguishes it from older GHRPs like GHRP-2 and GHRP-6, which produce meaningful cortisol and prolactin elevations that can complicate long-term use. Ipamorelin is most commonly combined with CJC-1295 (a GHRH analog) to produce synergistic GH release through dual-pathway stimulation. The two peptides act on different receptors and when administered together produce GH output substantially greater than either compound alone. This combination has become one of the most widely used peptide protocols in anti-aging medicine and performance-oriented use. Ipamorelin was placed on the FDA Category 2 bulk drug substance list in 2023, restricting compounding pharmacy production, though regulatory status remained in flux following a February 2026 announcement from HHS regarding potential reinstatement of certain peptides.
CJC-1295
gh-secretagogue
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered to dramatically extend the half-life of natural GHRH signaling. Developed by ConjuChem Biotechnologies in the early 2000s, it exists in two distinct forms that are frequently confused: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC, also known as Modified GRF (1-29) or mod GRF 1-29. Understanding this distinction is essential — they share a name but have fundamentally different pharmacokinetic profiles. The DAC version uses a reactive chemical group called maleimidopropionic acid (MPA) that forms a covalent bond with serum albumin after injection. This albumin binding shields the peptide from enzymatic degradation and extends its half-life from minutes to 5.8-8.1 days (PMID: 16352683). Native GHRH has a half-life of approximately 7 minutes, making this roughly a 1,000-fold improvement in duration. The landmark Teichman et al. trial demonstrated that a single CJC-1295 DAC injection produced dose-dependent GH increases of 2- to 10-fold sustained for 6 or more days, with IGF-I levels rising 1.5- to 3-fold for 9-11 days (PMID: 16352683). The no-DAC version (mod GRF 1-29) has four amino acid substitutions at positions 2, 8, 15, and 27 that improve stability against dipeptidylpeptidase-IV (DPP-IV) cleavage compared to native GHRH, but without albumin binding, its half-life is approximately 30 minutes. This shorter duration preserves the natural pulsatile pattern of GH release — the body's own rhythm of GH spikes followed by quiet periods — which many researchers and clinicians consider preferable to the continuous elevation produced by the DAC form. A critical finding from the Ionescu and Frohman study confirmed that even the DAC version preserves GH pulsatility: basal GH levels increased 7.5-fold, but GH pulse frequency and magnitude remained unchanged, meaning the pituitary's natural secretory rhythm was maintained rather than overridden (PMID: 17018654). This is a meaningful safety distinction from exogenous HGH, which produces flat, supraphysiologic GH levels that suppress the body's own production. CJC-1295 has never been FDA-approved for any indication. A Phase II clinical trial of the DAC version for HIV-associated lipodystrophy was halted in July 2006 after a participant died hours after his 11th injection at an Argentine study site. The cause of death was confirmed as acute myocardial infarction. The attending physician attributed the MI to pre-existing asymptomatic coronary artery disease unrelated to CJC-1295 treatment. The study enrolled 192 HIV-positive participants with significant cardiovascular risk factors, and ConjuChem eventually went bankrupt without completing the trial. The FDA flagged cardiac concerns when reviewing CJC-1295 during the 2024 PCAC process, indicating the regulatory signal was not fully dismissed. This remains the only reported fatality associated with CJC-1295. CJC-1295 was placed on the FDA Category 2 bulk drug substance list in late 2023, effectively prohibiting compounding pharmacies from preparing it. In September 2024, the FDA referred it to the Pharmacy Compounding Advisory Committee (PCAC), which flagged cardiac side effects and immunogenicity concerns. On February 27, 2026, HHS Secretary RFK Jr. announced that approximately 14 of 19 restricted peptides would return to legal compounding status, though the specific list has not been officially published and CJC-1295's inclusion remains uncertain due to its cardiac flagging. CJC-1295 is prohibited at all times by WADA under S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics.
BPC-157
healing-recovery
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a protective protein found naturally in human gastric juice. First isolated and characterized by researcher Predrag Sikiric and his team at the University of Zagreb in the early 1990s, BPC-157 has become one of the most extensively studied peptides in preclinical research, with over 100 published studies investigating its effects across multiple organ systems. The compound earned the nickname "the Wolverine peptide" in biohacking communities due to the breadth of tissue repair observed in animal studies. Research spanning more than three decades has documented effects on tendons, ligaments, muscles, bones, skin, corneas, the gastrointestinal tract, liver, and nervous system in preclinical models. A 2025 systematic review published in HSS Journal (PMID: 40756949) analyzed 36 studies conducted between 1993 and 2024, finding that BPC-157 consistently improved outcomes across musculoskeletal injury models. Despite this extensive preclinical evidence, human clinical data remains extremely limited. As of March 2026, only three small human studies have been published: a 2-person intravenous safety pilot (PMID: 40131143), a small retrospective knee pain study, and a 12-patient interstitial cystitis pilot. The knee pain study reported significant relief in most participants at 6-12 months, and the cystitis pilot reported substantial symptom improvement. Neither of these smaller studies has been published with full peer-reviewed PMIDs. A Phase I safety trial (NCT02637284) was registered by PharmaCotherapia but the sponsor never published results, raising transparency concerns in the research community. BPC-157 is classified as a research compound and is not FDA-approved for any human use. In 2023, the FDA placed BPC-157 in Category 2 of its list of bulk drug substances under evaluation for compounding, meaning it does not meet safety criteria for pharmacy compounding. The World Anti-Doping Agency (WADA) added BPC-157 to its prohibited substances list in 2022 under the S0 category (non-approved substances). Despite these regulatory designations, BPC-157 continues to be widely discussed in peptide research communities and functional medicine circles. The compound is available in injectable and oral forms. Most preclinical research has used subcutaneous or intraperitoneal injection, though studies have also demonstrated activity when administered orally, particularly for gastrointestinal conditions. An important distinction exists between the acetate salt and arginate salt forms. The arginate form reportedly demonstrates significantly better oral bioavailability and stability, though head-to-head bioavailability studies have not been published in peer-reviewed journals. A comprehensive preclinical safety evaluation published in Regulatory Toxicology and Pharmacology (PMID: 32334036) tested BPC-157 across multiple species including mice, rats, rabbits, and dogs. The study found no test-related adverse effects in single-dose or repeated-dose toxicity evaluations, no genetic toxicity, and no embryo-fetal toxicity at doses up to 20 mg/kg over six weeks. However, the absence of large-scale human safety trials means that the long-term safety profile in humans remains unknown. The primary mechanisms through which BPC-157 appears to exert its effects involve the promotion of angiogenesis, modulation of nitric oxide synthesis through multiple pathways, upregulation of growth factor receptors, and interaction with the dopamine and serotonin neurotransmitter systems. These mechanisms have been documented across dozens of studies spanning multiple research groups. BPC-157 occupies a unique position in the peptide landscape. Its broad preclinical evidence base across tissue types, combined with the near-total absence of human clinical trials, creates a significant gap between what animal research suggests and what has been demonstrated in people. All information on this page reflects published research and is presented for educational purposes only.
TB-500
healing-recovery
TB-500 is a synthetic version of Thymosin Beta-4 (Tb4), a naturally occurring 43-amino-acid protein that constitutes 70-80% of all beta-thymosins in the human body (PMID: 36464872). While the name "TB-500" is sometimes described as a fragment, most commercial TB-500 products contain the full 43-amino-acid Thymosin Beta-4 sequence. The key active region is the actin-binding domain (amino acids 17-23, the sequence LKKTETQ), which is responsible for promoting cell migration, angiogenesis, and tissue repair — the properties that have driven research interest since the early 2000s. Thymosin Beta-4 was originally isolated from the thymus gland in 1981 and initially studied for its role in immune function. Researchers later discovered broader tissue repair properties, leading to the foundational dermal wound study (PMID: 12581423) which demonstrated accelerated wound closure through enhanced cell migration, collagen deposition, and new blood vessel formation in animal models. This established the mechanistic rationale for all subsequent TB-500 research. The only published human clinical trials for Thymosin Beta-4 are in ophthalmology. RegeneRx Biopharmaceuticals developed RGN-259, a topical eye drop formulation containing 0.1% Thymosin Beta-4, which completed two Phase 2 randomized controlled trials for dry eye disease. The first trial in severe dry eye patients including those with graft-versus-host disease showed a 35.1% reduction in ocular discomfort and 59.1% reduction in corneal staining versus placebo (PMID: 25826322). A second trial in 72 subjects showed a 27% reduction in discomfort scores described as safe and well tolerated (PMID: 26056426). Note: primary endpoints in the second trial did not reach significance, though secondary endpoints showed improvement. Effects from the first trial persisted 28 days after treatment ended. Three subsequent Phase 3 dry eye trials (ARISE-1, -2, -3) did not meet their pre-specified co-primary endpoints, though secondary endpoints showed some statistical significance in pooled analyses. Cardiac repair represents the most researched preclinical application. Multiple animal studies demonstrate that Thymosin Beta-4 protects cardiac tissue after myocardial infarction by reducing oxidative damage, inhibiting fibrosis, and promoting new blood vessel formation (PMID: 35712678, 34335970). RegeneRx developed a clinical program for acute myocardial infarction treatment and completed Phase 1 safety protocols, but Phase 2 cardiac trial results were never published and the program appears to have stalled. Hair growth is another well-researched preclinical area. Mouse studies show that Thymosin Beta-4 overexpression leads to faster hair re-growth, higher hair shaft counts, and follicle clustering through P38/ERK/AKT/VEGF signaling pathways (PMID: 26083021). A 2021 review confirmed that exogenous Tb4 accelerates hair follicle cycle transitions and promotes migration of hair follicle stem cells (PMID: 33393222). No human hair growth trials have been published. A 2024 pharmacokinetic study introduced a finding that may reframe understanding of how TB-500 works: the metabolite Ac-LKKTE — not the parent TB-500 molecule — showed significant wound repair activity in vitro (PMID: 38382158). This suggests TB-500's reported effects in earlier studies may have been driven by its metabolic breakdown products rather than the intact peptide. Thymosin Beta-4 also demonstrates potent anti-fibrotic properties. It prevents fibrosis across multiple organ systems in animal models, and its N-terminal fragment Ac-SDKP can not only prevent but reverse established fibrosis in liver, lung, heart, and kidney tissue (PMID: 36580759). TB-500 is not FDA-approved for any indication. The FDA classified it as a Category 2 compound, restricting it from compounding pharmacy preparation. In February 2026, the Department of Health and Human Services announced plans to potentially reclassify certain peptides including Thymosin Beta-4, which could affect future regulatory accessibility. TB-500 is prohibited by the World Anti-Doping Agency (WADA) at all times as a Non-Specified Substance under category S2 (Peptide Hormones, Growth Factors, and Related Substances), with first-offense violations carrying a four-year ban. The U.S. Department of Defense has adopted WADA categories, making TB-500 prohibited for all military personnel. Despite its research-only status, TB-500 has been widely used in veterinary medicine, particularly in equine practice for soft tissue injuries — one of the earliest real-world applications that drove interest in human research. The combination of TB-500 with BPC-157, commonly called the "Wolverine Stack" in peptide communities, is one of the most discussed recovery-focused protocols, though no published studies have tested this combination in humans or animals.
Tesamorelin
gh-secretagogue
Tesamorelin (brand name Egrifta) is a stabilized synthetic analog of growth hormone-releasing hormone (GHRH) and the only FDA-approved GH secretagogue currently on the market. The FDA approved it in November 2010 for reducing excess abdominal fat in HIV-infected patients with lipodystrophy, a condition where antiretroviral therapy redistributes fat from the limbs to the abdomen and trunk. This approval rests on two pivotal Phase 3 trials published in the New England Journal of Medicine showing tesamorelin produced a 15-18% reduction in visceral adipose tissue (VAT) compared to placebo over 26 weeks (PMID: 20395564). Tesamorelin is a 44-amino acid peptide, identical in length to endogenous GHRH, with a trans-3-hexenoic acid modification on the N-terminus that slows enzymatic degradation and extends its half-life. Unlike sermorelin (29 amino acids) or CJC-1295 (which extends half-life through albumin binding), tesamorelin achieves its stability through chemical modification of the peptide backbone itself. It acts exclusively on the GHRH receptor (GHRHR) using the same mechanism as endogenous GHRH, stimulating pituitary somatotrophs to release GH in the body's natural pulsatile pattern while preserving the somatostatin feedback loop. Beyond its approved lipodystrophy indication, tesamorelin has been studied in two additional populations: healthy older adults and patients with mild cognitive impairment (MCI). A large NIH-funded 152-subject RCT found that 20 weeks of tesamorelin significantly improved executive function (P = 0.005) across both healthy aging and MCI groups, with no worsening of glucose tolerance in non-diabetic subjects (PMID: 22869065). A separate RCT found it significantly increased muscle density and lean muscle area across four trunk muscle groups in HIV patients compared to placebo (PMID: 31237318). These findings have driven off-label interest in anti-aging and cognitive health applications.
Get the Muscle Growth cheat sheet
Dosing quick-reference, key studies, and side effect management — in your inbox.
Recommended stacks
GH Optimization Stack
intermediate — $100-250
Growth hormone secretagogue stack combining GHRP and GHRH for synergistic GH release without exogenous HGH.
Body Recomposition Stack
intermediate — $250-500
Simultaneous fat loss and muscle preservation/growth protocol combining GH optimization with targeted fat metabolism.
Sleep & Recovery Stack
beginner — $60-120
Optimize deep sleep and overnight recovery using GH peptides timed to amplify the natural nighttime growth hormone surge.
The GH Optimization Stack
intermediate — $100-250
The most popular growth hormone secretagogue combination. CJC-1295 (a GHRH analog) and ipamorelin (a GHRP) work through complementary receptor pathways to produce synergistic GH release without the side effects of exogenous HGH.
The Muscle Growth Stack
advanced — $250-500
Combines GH secretagogues with IGF-1 LR3 for maximum anabolic signaling. CJC-1295 and ipamorelin elevate natural GH production, while IGF-1 LR3 provides direct muscle-building stimulus through insulin-like growth factor receptor activation.
Explore other goals
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026